Virtual reality headset aims to restore lost vision
NCT ID NCT07185971
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a virtual reality headset therapy called PAVE for people with chronic vision loss from stroke, traumatic brain injury, or brain surgery. Twenty participants will use the headset three times a week for eight weeks to see if it expands their field of view. The goal is to find a safe, drug-free way to improve daily visual function.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- virtual reality visual stimulation device
- What this could lead to
- If it works, this could offer a non-invasive way to partially restore vision in people with long-term visual field loss after brain injury.
- What could go wrong
- This is a very small early study with only 20 participants and no control group, so results may not be conclusive. The therapy requires frequent sessions and may not help everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * This study will include patients at least 6 months after the CVA or TBI or brain surgery event and up to ten (10) years after onset * The patients shall have a definitive diagnosis of homonymous hemianopia or quadrantanopia or generalized constriction. Exclusion Criteria: * Presence of any physical, neurological, or mental disability that would interfere with receiving the therapy. * Concurrent use of another visual therapy * Concurrent use of medications judged to affect training (amphetamines, dopamine, etc.) * Presence of ocular or neurological conditions that would interfere with training or cause a visual impairment including no residual vision, disorders of the eye, non-optic nerve heteronymous visual field defects * Insufficient fixation ability * Use of life supporting external medical device such as infusion pumps, ventricular assist devices, etc. * Presence of active implantable medical device including but not limited to cardiac pacemakers, defibrillators, nerve stimulators, cochlear implants, etc. * Subjects with known photosensitive epilepsy. * Subjects with chronic active infections on the head and face should be excluded from the study * Patients with known immune disorders for whom an infection could be life threatening should be excluded from the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Homonymous hemianopsia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Dr. D. M. Fitzgerald & Associates
RECRUITINGCedar Rapids, Iowa, 52404, United States
-
Neuro-Vision Associates of North Texas
RECRUITINGProspect, Kentucky, 40059, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.